B. Metzler seel. Sohn & Co. AG Buys New Shares in Kenvue Inc. $KVUE

Key Points

• B. Metzler seel. Sohn & Co. AG purchased 120,727 Kenvue shares worth approximately $2.3 million during the second quarter. Institutional investors collectively own 97.64% of the company.
• Kenvue’s latest quarterly results slightly missed expectations, with EPS of $0.31 versus $0.32 expected and revenue of $3.96 billion versus $3.97 billion estimated; revenue nevertheless increased 3% year over year.
• The company’s quarterly dividend is $0.21 per share, equivalent to an annualized yield of about 4.4%. Analysts remain broadly neutral, with an average “Hold” rating and a $19.27 price target compared with the stock’s $19.08 price.

B. Metzler seel. Sohn & Co. AG purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 120,727 shares of the company's stock, valued at approximately $2,307,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. raised its holdings in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Kenvue during the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new position in Kenvue in the second quarter valued at approximately $26,000. MV Capital Management Inc. bought a new position in Kenvue in the fourth quarter valued at approximately $28,000. Finally, CoreCap Advisors LLC increased its position in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after purchasing an additional 591 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 0.8%

KVUE opened at $19.08 on Friday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.78. The stock's fifty day simple moving average is $19.05 and its 200 day simple moving average is $18.19. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a market cap of $36.65 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be paid a $0.21 dividend. This is an increase from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue's dividend payout ratio (DPR) is currently 96.55%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KVUE shares. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Zacks Research lowered shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Wall Street Zen cut shares of Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. Finally, UBS Group lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source